ERBB2 and neoplasm: Given the lack of primary tumor cells and reliable technology to determine the TCR-specificity of the immunodominant clones identified after HER2 CAR T-cell infusion in this patient, our observations currently remain descriptive but warrant further studies, ideally in a larger cohort of responding and non-responding patients.